Latest & greatest articles for quetiapine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on quetiapine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on quetiapine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for quetiapine

22. Efficacy of quetiapine monotherapy in rapid-cycling bipolar disorder in comparison with sodium valproate

Efficacy of quetiapine monotherapy in rapid-cycling bipolar disorder in comparison with sodium valproate 18794653 2008 09 16 2008 11 24 2015 11 19 1533-712X 28 5 2008 Oct Journal of clinical psychopharmacology J Clin Psychopharmacol Efficacy of quetiapine monotherapy in rapid-cycling bipolar disorder in comparison with sodium valproate. 555-60 10.1097/JCP.0b013e318185e75f Rapid-cycling bipolar disorder is often characterized by a lack of response to psychopharmacological treatment (...) , and a standard therapy has not been developed yet. The aim of this study was to examine the long-term efficacy and safety of a monotherapy with quetiapine or sodium valproate (VPA) in patients with rapid-cycling bipolar disorder. This open-label, randomized, parallel group monotherapy pilot study was conducted at 3 German centers. A sample of 38 remitted or partly remitted patients with bipolar disorder and rapid cycling (quetiapine n = 22; VPA n = 16) were treated with quetiapine or VPA (flexible dose

EvidenceUpdates2008

23. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study

Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study 18794652 2008 09 16 2008 11 24 2015 11 19 1533-712X 28 5 2008 Oct Journal of clinical psychopharmacology J Clin Psychopharmacol Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. 550-4 10.1097/JCP.0b013e318185e735 Although many (...) patients with obsessive-compulsive disorder (OCD) benefit from treatment with serotonin reuptake inhibitors (SRIs), it is estimated that 40% to 60% of them do not respond. The objective of the present study was to evaluate the efficacy of quetiapine added to baseline treatment with SRIs for the treatment of OCD in severely ill adult subjects. Forty patients (21 men, 19 women) with primary OCD according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria participated

EvidenceUpdates2008

24. Quetiapine more effective than placebo for depression in bipolar I and II disorder

Quetiapine more effective than placebo for depression in bipolar I and II disorder Quetiapine more effective than placebo for depression in bipolar I and II disorder | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main (...) menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Quetiapine more effective than placebo for depression in bipolar I and II disorder Article Text Therapeutics Quetiapine more effective than placebo for depression in bipolar I and II disorder Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you wish to reuse any or all of this article

Evidence-Based Mental Health2008

25. Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia

Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia Article Text Therapeutics Haloperidol, olanzapine and risperidone reduce

Evidence-Based Mental Health2008

26. Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia

Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia Article Text Therapeutics Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you wish to reuse any

Evidence-Based Mental Health2008

27. Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia

Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia 18204344 2008 01 21 2008 03 27 2015 11 19 0271-0749 28 1 2008 Feb Journal of clinical psychopharmacology J Clin Psychopharmacol Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia. 69-73 10.1097/jcp.0b013e318160864f Persistent neuroleptic-induced movement disorders limit effective pharmacological management of psychotic (...) disorders. Although antipsychotic switching is a common strategy for managing extrapyramidal side effects (EPSs), there is insufficient empirical support to guide the clinician. We designed the present study to examine whether patients with preexisting EPS switched to quetiapine would show greater reduction in EPS compared with control patients. Twenty-two patients with schizophrenia meeting clinical criteria for tardive dyskinesia or coexisting parkinsonism were randomized either to switch from

EvidenceUpdates2008

28. Quetiapine for acute mania in bipolar disorder

Quetiapine for acute mania in bipolar disorder Quetiapine for acute mania in bipolar disorder Quetiapine for acute mania in bipolar disorder Brahm N C, Gutierres S L, Carnahan R M Authors' objectives To evaluate the safety and efficacy of quetiapine as a treatment for acute mania in bipolar disorder. Searching MEDLINE, Cochrane Database of Systematic Reviews, ACP Journal Club, DARE, Cochrane Controlled Trials Registry and International Pharmaceutical Abstracts databases were searched to 2006 (...) . Search terms were reported. Manufacturers' websites were searched for unpublished and ongoing trials. Study selection Randomised double-blind placebo-controlled trials (RCTs) of quetiapine for the treatment of acute mania were eligible for inclusion. The included studies evaluated quetiapine as monotherapy (400 mg/day to 800 mg/day). Some studies compared quetiapine with another pharmacological agent, such as lithium (serum concentration 0.6 meq/L to 1.4 meq/L) and haloperidol (4 mg/day to 8 mg/day

DARE.2007

29. Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials

Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials Fineberg N A, Stein D J, Premkumar P (...) , Carey P, Sivakumaran T, Vythilingum B, Seedat S, Westenberg H, Denys D CRD summary The authors concluded that there was limited evidence that adjunctive quetiapine is effective for patients with obsessive-compulsive disorder who are unresponsive to serotonin re-uptake inhibitors. The conclusions about limited evidence appear to reflect findings from three small studies, but poor reporting of the review methods and differences between the included studies make it difficult to assess their reliability

DARE.2006

30. Budgetary impact of treating acute bipolar mania in hospitalized patients with quetiapine: an economic analysis of clinical trials

Budgetary impact of treating acute bipolar mania in hospitalized patients with quetiapine: an economic analysis of clinical trials Budgetary impact of treating acute bipolar mania in hospitalized patients with quetiapine: an economic analysis of clinical trials Budgetary impact of treating acute bipolar mania in hospitalized patients with quetiapine: an economic analysis of clinical trials Caro J J, Huybrechts K F, Xenakis J G, O'Brien J A, Rajagopalan K, Lee K Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined quetiapine, an atypical antipsychotic for the treatment of bipolar mania. Different scenarios were considered on the basis of the proportion of patients using quetiapine with respect to other standard

NHS Economic Evaluation Database.2006

31. Schizophrenia: risperidone and olanzapine increase time to discontinuation compared with quetiapine and ziprasidone

Schizophrenia: risperidone and olanzapine increase time to discontinuation compared with quetiapine and ziprasidone Schizophrenia: risperidone and olanzapine increase time to discontinuation compared with quetiapine and ziprasidone | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Schizophrenia: risperidone and olanzapine increase time to discontinuation compared with quetiapine and ziprasidone Article Text Therapeutics Schizophrenia: risperidone and olanzapine increase time to discontinuation compared with quetiapine and ziprasidone Statistics from

Evidence-Based Mental Health2006

32. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol

Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol Kongsakon R, Leelahanaj T, Price N (...) , Birinyi-Strachan L, Davey P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Several medications for schizophrenia were examined. The four atypical antipsychotics studied were olanzapine (OLZ), risperidone (RISP), quetiapine (QUET

NHS Economic Evaluation Database.2005

33. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial.

Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. 15722369 2005 04 15 2005 04 26 2015 11 19 1756-1833 330 7496 2005 Apr 16 BMJ (Clinical research ed.) BMJ Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. 874 To determine the respective efficacy of quetiapine and rivastigmine for agitation in people with dementia in institutional care (...) and to evaluate these treatments with respect to change in cognitive performance. Randomised double blind (clinician, patient, outcomes assessor) placebo controlled trial. Care facilities in the north east of England. 93 patients with Alzheimer's disease, dementia, and clinically significant agitation. Atypical antipsychotic (quetiapine), cholinesterase inhibitor (rivastigmine), or placebo (double dummy). Agitation (Cohen-Mansfield agitation inventory) and cognition (severe impairment battery) at baseline

BMJ2005 Full Text: Link to full Text with Trip Pro

35. Quetiapine for schizophrenia.

Quetiapine for schizophrenia. BACKGROUND: Quetiapine is an atypical antipsychotic with, theoretically, a low propensity for movement disorder adverse effects. It is used for the treatment of schizophrenia and other psychoses. OBJECTIVES: To determine the effects of quetiapine for schizophrenia in comparison to placebo, and other antipsychotics. SEARCH STRATEGY: Electronic searches of the Cochrane Schizophrenia Group's Register of Trials (February 2003), Biological Abstracts (1982-2000), CINAHL (...) to quetiapine, placebo or other neuroleptic drugs and where clinically relevant outcomes were reported. DATA COLLECTION AND ANALYSIS: Citations and, where possible, abstracts were inspected independently by reviewers, papers ordered, re-inspected and quality assessed. We independently extracted data. We analysed data using fixed effects relative risk (RR) and estimated the 95% confidence interval (CI). Only homogeneous data were interpreted as favouring treatment or control. Where possible we calculated

Cochrane2004

36. An economic assessment of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics

An economic assessment of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics An economic assessment of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics An economic assessment of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics Tilden D, Aristides M, Meddis D, Burns T Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of quetiapine versus haloperidol for the treatment of patients with schizophrenia who were only partially responsive to conventional antipsychotics. Type of intervention Treatment. Economic study type Cost

NHS Economic Evaluation Database.2002

37. The health economic implications of treatment with quetiapine: an audit of long-term treatment for patients with chronic schizophrenia

The health economic implications of treatment with quetiapine: an audit of long-term treatment for patients with chronic schizophrenia The health economic implications of treatment with quetiapine: an audit of long-term treatment for patients with chronic schizophrenia The health economic implications of treatment with quetiapine: an audit of long-term treatment for patients with chronic schizophrenia Lynch J, Morrison J, Graves N, Meddis D, Drummond M F, Hellewell J S E Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of quetiapine ('Seroquel'), a new atypical antipsychotic, in patients with chronic schizophrenia. The dosage was 150 to 750 mg/day. Type of intervention Treatment. Economic study type Cost-effectiveness

NHS Economic Evaluation Database.2001

38. Quetiapine for schizophrenia.

Quetiapine for schizophrenia. BACKGROUND: Quetiapine is a novel atypical antipsychotic with low propensity for movement disorder adverse effects. It is used for treatment of schizophrenia and other psychoses. OBJECTIVES: To determine the effects of quetiapine for schizophrenia in comparison to placebo, classical and other atypical antipsychotics. SEARCH STRATEGY: Electronic searches of Biological Abstracts (1982-1997), CINAHL (1982-1997), the Cochrane Library (1998, Issue 1), the Cochrane (...) Schizophrenia Group's Register of trials (1998), EMBASE (1980-1998), MEDLINE (1966-1998), PsycLIT (1974-1997), SocioFile (1974-1997) and many conference proceedings and hand searches of specific journals were undertaken. Zeneca Pharmaceuticals was contacted for information regarding unpublished trials. SELECTION CRITERIA: All controlled trials where adults with schizophrenia or similar illnesses were randomised to quetiapine, placebo or other neuroleptic drugs and where clinically relevant outcomes were

Cochrane2000

39. Quetiapine for schizophrenia.

Quetiapine for schizophrenia. BACKGROUND: Quetiapine is a novel atypical antipsychotic with, theoretically, a low propensity for movement disorder adverse effects. It is used for treatment of schizophrenia and other psychoses. OBJECTIVES: To determine the effects of quetiapine for schizophrenia in comparison to placebo, classical and other atypical antipsychotics. SEARCH STRATEGY: Electronic searches of Biological Abstracts (1982-2000), CINAHL (1982-2000), the Cochrane Library (2000, Issue 1 (...) ), the Cochrane Schizophrenia Group's Register of trials (Feb 2000), EMBASE (1980-2000), MEDLINE (1966-2000), PsycLIT (1974-2000), SIGLE on CD (1980-1997), SocioFile (1974-1997) and many conference proceedings and hand searches of specific journals were undertaken. AstraZeneca Pharmaceuticals was contacted for information regarding unpublished trials. SELECTION CRITERIA: All controlled trials where adults with schizophrenia or similar illnesses were randomised to quetiapine, placebo or other neuroleptic drugs

Cochrane2000

40. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials Efficacy and extrapyramidal side-effects of the new (...) antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials Leucht S, Pitschel-Walz G, Abraham D, Kissling W Authors' objectives To summarise the efficacy and tolerability of the new antipsychotics risperidone, olanzapine, sertindole and quetiapine in schizophrenia compared to placebo and conventional antipsychotics. Searching MEDLINE (1966-January 1998) and Current Contents (1966-March 1998) were

DARE.1999